AMTI - Applied Molecular gets dosing underway in early-stage AMT-126 study

Applied Molecular Transport (AMTI) announces that the first patient has been dosed in its Phase 1a clinical trial of oral AMT-126, a novel, gastrointestinal ((GI))-selective oral fusion of human interleukin-22 ((hIL-22)).The company expects complete data from its oral AMT-126 Phase 1a/b study in 2022.The randomized, placebo controlled, single ascending dose Phase 1a trial is evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of AMT-126 in up to 50 healthy volunteers.The company also said that it remains on track to announce data readouts from its mid-stage trials of inflammatory bowel diseases and rheumatoid arthritis treatment AMT-101 in the second half of this year.

For further details see:

Applied Molecular gets dosing underway in early-stage AMT-126 study